研報掘金丨國盛證券:長春高新主業有望企穩,維持“買入”評級
國盛證券研報指出,長春高新(000661.SZ)為百億生長激素龍頭,主業有望企穩。基於目前實際患者用藥情況及潛在市場空間等,公司對於生長激素產品銷售持理性態度,並將持續積極推進相關產品銷售工作,努力確保核心產品經營穩定;同時,公司將繼續拓展長效生長激素新適應症,積極開拓新領域、新市場,成人生長激素缺乏適應症處於Ⅲ期臨牀試驗階段;與司美格魯肽聯合用藥用於增肌減脂相關適應症,目前處於研究者發起的臨牀研究。考慮目前公司處於創新轉型階段,公司佈局平衡短期業績與長期發展,目前各項費用投放較高,預計2025-2027年公司歸母淨利潤分別為20.59億元、21.11億元、24.30億元,對應增速分別為-20.3%,2.5%,15.1%。維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.